Belimumab 4 mg/kg

DRUG2 trials

Sponsors

Human Genome Sciences Inc.

Conditions

Arthritis, RheumatoidLupus Erythematosus, Systemic

Phase 2

Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)

CompletedNCT00071487

Human Genome Sciences Inc.Lupus Erythematosus, Systemic

Start: 2003-10-31End: 2006-06-30Updated: 2013-08-07

A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

CompletedNCT00071812

Human Genome Sciences Inc.Arthritis, Rheumatoid

Start: 2003-12-31End: 2005-12-31Updated: 2013-08-14

Related Papers

PO:15:217 | Improved efficacy and safety outcomes in patients with systemic lupus erythematosus treated with belimumab vs. immunosuppressants, in addition to antimalarials and glucocorticoids: a <i>post-hoc</i> summary of five phase 3 trials

Reumatismo2025-11-26

Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.

2024-09-017 citations

Usefulness of Belimumab in Adult Patients With Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Review

Current Therapeutic Research2024-01-013 citations

Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus

Drugs in R&D2021-10-094 citations

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison

RMD Open2021-09-0128 citations

Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus

The Journal of Rheumatology2013-11-01179 citations

Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.

2013-04-0174 citations